CME (CME) Q1 2026 Earnings Call Transcript

CME Group reported record 2024 results with revenue up 10% to $6.1B, adjusted net income of $3.7B, and adjusted operating margin expanding 140+ bps to 68.3%, while Q4 revenue rose 6% and adjusted EPS increased 6% to $2.52. Management guided 2025 adjusted expenses to about $1.65B, capex to $90M, and described fee changes plus the new collateral surcharge as potentially adding 2%-2.5% to pre-tax income. The company also highlighted strong retail and international growth, a $3B buyback authorization, and continued momentum in commodities, crypto, and market data.

Analysis

CME is doing something more important than simply monetizing higher volatility: it is widening the moat around its clearing franchise by making the product ecosystem stickier. The fee changes matter, but the real second-order effect is behavioral — pushing more collateral into cash and drawing more client activity into higher-frequency, retail- and buy-side-friendly contracts increases both recurring revenue and balance-sheet control. That mix should support a higher-quality earnings stream than the headline volume growth alone suggests.

The clearest competitive tell is that CME is not trying to win the same customer with the same product; it is segmenting by use case. Retail growth via micros, crypto, and commods, plus buy-side demand in ags/metals, creates a flywheel where new clients begin in simple, liquid contracts and then expand into options and adjacent markets. That makes smaller rival venues and bilateral venues less relevant over time, while also pressuring OTC intermediaries whose value proposition weakens when clients can hedge more efficiently on-exchange.

The main risk is that management is leaning heavily on a continuation of “good volatility” — tariffs, geopolitics, weather, and policy uncertainty — and that narrative can fade quickly if macro conditions stabilize. Another underappreciated risk is that the collateral surcharge could trigger customer optimization away from non-cash balances faster than expected, muting the intended revenue uplift while still increasing client pushback. The catalyst path is near-term: January/February volumes, retail broker rollouts, and the April collateral change are the key checkpoints over the next 1-2 quarters.

Consensus may be underestimating how much this is a capital-efficiency story rather than a pure volumes story. If securities clearing and broader cross-margining gain traction, CME’s optionality expands beyond trading fees into balance-sheet optimization, which tends to command a higher multiple because it is harder to replicate. The market may also be too slow to price the compounding effect of market data, education, and cloud migration turning CME into a more integrated data-and-workflow platform for professional retail and buy-side clients.

Key Decisions for Investors

• Long CME on a 3-6 month horizon; the setup favors a low-volatility compounder with operating leverage to fees, data, and capital returns. Risk/reward skews positive if volumes remain firm and the April collateral change lands without meaningful client attrition.
• Buy CME Jan-2027 calls / finance with shorter-dated upside sales if implied vol is reasonable; this captures the multi-quarter monetization of fee changes, retail rollout, and securities-clearing optionality with limited downside.
• Pair trade: long CME / short ICE for the next 2-4 quarters. CME has clearer near-term monetization from collateral, retail growth, and capital returns, while ICE is more exposed to slower-moving structural growth and integration risk.
• For a tactical trade, add on any post-earnings or post-April collateral-change weakness if the stock derates on perceived customer pushback. The fundamental read-through is that even modest mix shifts into cash and higher-RPC products should offset most volume elasticity.
• Avoid chasing pure beta names in OTC/market-structure intermediaries against CME. CME’s moat is expanding through clearing, data, and cross-margining, making it the cleaner way to express higher volatility without taking directional commodity risk.